Korea’s health supplement (health functional food, or geongi-sik) sector has seen a broad-based earnings slowdown across listed companies. Revenue and operating profit are declining in tandem — and that’s prompting investors to look beyond the numbers and ask a more fundamental question: who actually makes money in this industry, and why?
This post breaks down the Korean health supplement industry structure across four value chain stages — ingredient, ODM manufacturing, brand, and distribution — and identifies the key investment angles worth watching.
How the Industry Makes Money — The 4-Stage Value Chain
The Korean health supplement industry is organized around the following value chain:
Ingredient → ODM Manufacturing → Brand → Distribution
| Stage | Role | Key Characteristics | Investment Profile |
|---|---|---|---|
| Ingredient | Develop & supply functional materials | High barriers via patents & clinical data | High margins, durable moat |
| ODM | Contract manufacturing for brands | Volume-driven, order-dependent | Stable but limited upside |
| Brand | Direct consumer sales | Marketing & channel execution is everything | High margin potential, high cost base |
| Distribution | Home shopping, online channels | Highly sensitive to channel dynamics | Channel-dependent revenue |
From an investment standpoint, ingredient companies tend to generate the highest returns on capital — their moats are structural, not just cyclical. ODM manufacturers offer stability with limited growth optionality. Brand companies can be high-margin but carry significant marketing cost risk.
Why the Market Has Stalled — 4 Structural Headwinds
The earnings weakness across listed health supplement companies isn’t random. Four structural forces are at work.
① Post-COVID Demand Normalization
During 2020–2022, immunity-related supplement demand surged sharply. That tailwind is gone. Companies are now navigating a tough base effect as demand reverts to pre-pandemic levels, compressing year-on-year comparisons.
② Market Saturation — Limited Room for New Buyers
Korea is one of the highest per-capita health supplement consuming countries in the world. The vast majority of households have already purchased supplements, leaving little room for demand growth driven by new consumer acquisition.
③ Brand Proliferation and Order Fragmentation
The number of supplement brands has grown rapidly in recent years — influencer-driven labels, home shopping private brands, and D2C online players have all entered the space. For ODM manufacturers, this means orders are spread thinner across more clients, and pricing power is gradually eroding.
④ Weakening Home Shopping Channel
Home shopping has historically been a dominant distribution channel for Korean health supplements. That’s changing fast. As consumers shift to online and D2C, companies with heavy home shopping exposure are feeling disproportionate pain.
A Defining Structural Feature: Korea Is an ODM-First Market
Compared to global peers, the most distinctive feature of the Korean health supplement industry structure is its exceptional manufacturing depth.
| Segment | Korea’s Competitive Position |
|---|---|
| Ingredient R&D | Relatively underdeveloped vs. global leaders |
| ODM Manufacturing | Very strong — globally competitive production capabilities |
| Brand | A few large players; fragmented overall |
| Distribution | Home shopping historically dominant; now in structural decline |
The Korean market is built around ODM manufacturing. That explains both the relative weakness in ingredient IP and branding — and also why companies that have managed to build proprietary ingredient portfolios deserve a meaningful premium.
Key Listed Companies — Where They Sit in the Value Chain
ODM Manufacturers — Kolmar BNH · Novarex · Seohung
Kolmar BNH, Novarex, and Seohung are the core ODM players in the Korean supplement space. Their model is straightforward: manufacture products on behalf of brand clients. As brand proliferation continues, ODM demand may increase in volume — but pricing pressure from a fragmented client base is a real counterweight. The distinction between pure-play ODM and ODM-with-ingredients (see below) matters significantly for valuation.
Ingredient-Based Business — HL Science
HL Science holds approximately 10 individually recognized functional ingredients approved by Korea’s MFDS (Ministry of Food and Drug Safety). It operates both a B2B ingredient supply model and a B2C product business. The B2B ingredient revenue stream provides meaningful insulation from consumer spending cycles — a differentiated profile versus pure ODM peers.
Probiotic Strain Specialist — Cell Biotech
Cell Biotech is a probiotic-focused company with proprietary lactic acid bacteria strains at the core of its business. The strain itself is the moat — competitors cannot easily replicate products built on a unique, clinically validated strain library. In terms of competitive structure, Cell Biotech shares characteristics with ingredient-based companies more than traditional ODM players.
The Most Important Investment Concept: Individually Recognized Ingredients
One concept that comes up repeatedly in Korean supplement investing — and is frequently misunderstood — is the distinction between individually recognized ingredients and standard notified ingredients.
| Type | Description | Barrier to Entry |
|---|---|---|
| Notified Ingredient | Publicly approved; any company can use | Low |
| Individually Recognized Ingredient | Requires clinical trials + MFDS approval; exclusive use rights for the applicant company | High |
Individually recognized ingredients require a company to run clinical trials demonstrating efficacy, submit for MFDS approval, and — once approved — that company holds exclusive usage rights for a defined period. The cost and time required to obtain approval create a natural, durable moat. The number of individually recognized ingredients a company holds is one of the most important indicators of its structural competitive advantage.
Companies with a large portfolio of individually recognized ingredients can charge premium prices without competing on cost. This is the fundamental reason why ingredient-capable companies should not be valued on the same basis as pure ODM manufacturers.
Individually Recognized Ingredient Portfolio — Company Comparison
| Company | Individually Recognized Ingredients | Business Model Notes |
|---|---|---|
| HL Science | ~10 ingredients | B2B ingredient supply + B2C product sales |
| Novarex | 40+ ingredients | Largest portfolio in Korea — ODM with proprietary ingredient depth |
| Cell Biotech | Strain-based ingredients | Probiotic specialist; strain library is the core asset |
By ingredient count, Novarex holds the largest portfolio of individually recognized ingredients among domestic peers. It should be analyzed not as a commodity ODM, but as an ingredient-enabled ODM — a meaningfully different valuation frame that is often overlooked by investors approaching the name for the first time.
How Korea Compares to the Global Market
Globally, the health supplement value chain is dominated at the top by ingredient companies. DSM-Firmenich and Kemin Industries, for example, supply raw functional materials to food and supplement companies worldwide — commanding significant pricing power and margin.
Korea has world-class ODM manufacturing capabilities, but lacks a globally scaled ingredient company of that type. That gap represents a structural long-term opportunity. Companies that combine proprietary ingredient development with overseas market access are the ones best positioned to capture it.
Three Business Models That Will Survive Long-Term
As the Korean health supplement market matures, competitive dynamics will increasingly favor three types of companies.
1) Proprietary Ingredient Companies
Companies with patent-protected, clinically validated functional ingredients. They compete on IP, not price — and their B2B supply model provides revenue stability that is less exposed to consumer sentiment.
2) Global ODM Manufacturers
ODM companies that have successfully diversified their client base beyond Korea. Export revenue as a percentage of total sales is the key metric to track here — it’s the clearest signal of a company’s ability to escape domestic market saturation.
3) Established Consumer Brands
Brands with strong consumer recognition that can retain loyalty even as distribution channels fragment. Channel diversification — particularly the degree to which a brand has reduced home shopping dependency — is the most important operational checkpoint.
Next Growth Frontiers — Probiotics and the Microbiome
Within the broader health supplement space, the following categories are attracting the most attention for medium-to-long-term growth:
- Probiotics — Already a growing category. Strain differentiation is becoming the key competitive variable.
- Collagen & Ingestible Beauty — The blurring of beauty and health is a durable consumer trend, particularly among younger female consumers.
- Postbiotics — Emerging as the next generation of probiotic-adjacent ingredients; watch for clinical validation activity.
- Microbiome — The highest-conviction long-term theme. Companies building microbiome platforms that extend from supplements into therapeutics have the potential for a significant valuation re-rating if clinical pipelines progress.
The microbiome angle in particular deserves close attention. If a Korean supplement company successfully bridges into drug development through its microbiome pipeline, the valuation framework changes entirely — from a consumer staples multiple to a biopharma multiple.
Conclusion — Where to Focus in Korean Health Supplement Investing
The Korean health supplement industry can be summarized in one sentence:
The companies that survive will be those with proprietary ingredient IP, global manufacturing reach, or a brand strong enough to transcend channel disruption — ideally more than one of the three.
Domestic market growth has structural limits. The next phase of value creation will come from three sources:
- Accumulation of individually recognized ingredient portfolios
- Expansion of overseas ODM client relationships
- Early positioning in next-generation categories, particularly microbiome
Mapping each listed company against these three criteria — rather than simply comparing revenue growth or trailing multiples — is what separates a structural view of this industry from a purely tactical one.